BlueWillow Biologics, Inc.

📍 United States👥 22 employees💰 Last funded 2017
Biotechnology Research🌐 bluewillow.com
Website LinkedIn
BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.
4
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
4
Investor activity2000–2017 · investors recorded per year
200012015220171
Recent (last 2y)Earlier
Frequently asked questions
Who invested in BlueWillow Biologics, Inc.?
BlueWillow Biologics, Inc. has 4 investors on record on gritt.io.
When did BlueWillow Biologics, Inc. last raise funding?
The most recent investment in BlueWillow Biologics, Inc. recorded on gritt.io was in 2017.
What industry is BlueWillow Biologics, Inc. in?
BlueWillow Biologics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is BlueWillow Biologics, Inc. based?
BlueWillow Biologics, Inc. is headquartered in United States.